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Noninvasive imaging of receptor function: signal transduction
pathways and physiological readouts
Abstract
Intracellular signaling describes the process of information propagation from the cell surface to the
location within the cell where a biological response is executed. Signaling pathways involve a complex
network of interacting molecular species. It is obvious that information on the activation of individual
pathways is highly relevant in biomedical research, both from a diagnostic point of view and for
evaluating therapeutic interventions. Modern molecular imaging approaches are capable of providing
such information in a temporo-spatially resolved manner. Two strategies can be pursued: imaging
individual pathway molecules or targeting protein-protein interactions, which are key elements of the
signaling networks. Assays such as fluorescence resonance energy transfer, two-hybrid, protein
fragment complementation or protein splicing have been adapted to allow studies in live mice. The
major issues in imaging signal transduction are sensitivity, as critical species occur at low concentration,
and the fact that the processes targeted are intracellular, that is, exogenous probes have to cross the cell
membrane. Currently, the majority of these imaging methods are based on genetic engineering
approaches and are therefore confined to experimental studies in animals. Exogenous probes for
targeting intracellular pathway molecules are being developed and may allow translation into the clinic.
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Abbreviations 
AD activator domain, DBD DNA-binding domain, MRI 
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complementation assay, PET positron emission tomography
Signal transduction
In this review, the term signal transduction is used for 
any process by which information is transferred from a 
site of signal generation (eg, a ligand-receptor interaction 
at the cell surface) to a site where a biological program 
is executed (eg, a gene transcription in the nucleus). A 
typical signal transduction cascade is initiated by the 
binding of extracellular signaling molecules, ie, receptor 
ligands such as hormones, growth factors, neurotransmitters 
and drugs, to cell surface receptors thereby triggering 
intracellular signaling. Signaling pathways involve a 
complex network of biochemical reactions that are 
carried out within a cell by enzymes such as kinases 
and phosphatases. Key elements of signal propagation 
within a cell are the interaction of proteins, as well as the 
reversible phosphorylation of proteins (Figure 1). The 
timescales of these processes range from milliseconds 
in the case of ion channel-mediated signaling, to minutes 
for the activation of kinase cascades, to several hours 
and even days for processes involving gene induction.
Signaling may prompt cellular responses such as the 
activation of genes, cell proliferation, the induction of 
apoptosis or adaptations/alterations in metabolism. The 
activation of genes will induce further downstream effects 
due to the function of the gene products (eg, transcription 
factors, enzymes). For example, hypoxia triggering 
the hypoxia-inducible factor (HIF) cascade leads to the 
induction of over 150 different gene products, including 
factors that stimulate angiogenesis and enzymes that 
increase anaerobic glycolysis [1]. Thus, an initial stimulus 
can induce a multitude of physiological responses. There 
is extensive literature on signal transduction to which the 
reader is referred for further details. This review focuses 
on strategies for imaging signaling pathways (see also 
[2••,3•]).
At a molecular level, disease processes are associated 
with altered levels of gene products, such as cell surface 
receptors, transporters or enzymes. The functional 
consequences of these altered levels of gene products are 
therefore aberrations in intra- and intercellular signaling. 
Hence, the quantitative assessment of cell signaling, 
for example, using imaging approaches, might be of 
high diagnostic value. Similarly, it is of relevance when 
evaluating therapeutic interventions. When analyzing 
treatment response, temporo-spatially resolved information 
on the biodistribution and pharmacokinetic properties of a 
drug, on the expression of the molecular drug target and 
on the interaction of the drug with its potential receptor 
should be complemented by quantitative measures 
of the functional consequences of this drug-receptor 
interaction. At a molecular level, such information could 
be provided by pathway imaging that assesses either 
key molecules in the signal transduction pathway or 
that specifically targets protein-protein interactions. 
Alternatively, metabolic or physiological processes that 
are the result of the activation of a specific signaling 
cascade might be assessed.
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Strategies for imaging signaling pathways 
Targeting individual pathway molecules 
The direct targeting approach focuses on specific molecular 
species in the signaling cascade, for example, caspases 
(death proteases) as central constituents of the apoptotic 
path. Individual proteins might be addressed using an 
exogenous ligand that contains a covalently-linked reporter 
group (a fluorescent dye, a para- or superparamagnetic 
moiety or a radionuclide) and that competes with 
endogenous ligands or substrates. Direct targeting 
using receptor ligands or enzyme inhibitor-based probes 
faces two issues. The detection of the target-specific 
interactions with a good signal-to-background ratio requires 
efficient clearance of the unbound or non-specifically 
bound fraction of reporter molecules, ie, favorable 
pharmacokinetic properties. The second issue with 
inhibitor-based probes is the lack of signal amplification: 
there is, in general, only one reporter molecule per molecular 
target, which will affect the sensitivity of the approach.
Alternatively, activatable reporter molecules can be used. 
These probes change their physicochemical properties upon 
interaction with their target. Prominent examples of this 
class of reporter moieties are quenched protease ligands. 
Figure 1. Schematic describing the signal transduction induced by a membrane-bound G-protein-coupled receptor. 
Interaction with a receptor ligand initiates a cascade of molecular events (protein activation, protein-protein interaction, etc) that propagates 
information from outside the cell to its destination, for example, the nucleus, prompting a system response. Imaging targets in signaling pathways 
for which assays have been developed are individual pathway proteins or protein-protein interactions.
(Reproduced with permission from the University of Zürich.  2008 University of Zürich).
Gγ
Receptor interaction
Signal transduction 
Transmembrane receptor:
eg, G-protein-coupled receptor Extracellular
Ligand
Gβ Gα
Gγ Gβ Gα
Src
Shc
Grb2
SOS
Ras
MEKK
SEK
SAPK
PKA
Myc
Raf
MEK
ERK
ATF2 TCFs cJun ELK1
Cytoplasm
Nucleus
DNA
Gene expression
Transcription
System response
Protein-protein
interaction
Pathway 
molecules
cAMP
pathways
NOT FOR CIRCULATIONNoninvasive imaging of receptor function: Signal transduction pathways and physiological readouts  Rudincle  3
Upon proteolytic cleavage of the construct, the fluorophor 
and quencher groups are separated and a fluorescent signal 
will be detected. The feasibility of this approach has been 
demonstrated using a cathepsin-activatable polymeric 
reporter substrate [4•]. As enzymes process a large number 
of substrate molecules, significant signal amplification 
might be achieved. In addition, the signal-to-background 
ratio was intrinsically high, because fluorescence is largely 
quenched in the absence of the enzyme.
A general issue with the direct targeting of pathway 
molecules using exogenous ligands is cell penetration as the 
imaging targets are invariably intracellular. 
Targeting protein-protein interactions 
Protein-protein interactions are key processes for information 
propagation along signaling cascades. Several strategies 
have been developed to probe these molecular events 
in cellular systems that sense the proximity of the two 
(or more) interacting partners. Some of these assays have 
been translated into in vivo imaging (Figure 2). All these 
assays depend on genetically modified cells or organisms, 
and thus constitute research tools. 
The most established method for targeting protein-protein 
interactions is fluorescence resonance energy transfer 
(FRET). Electronically excited dyes can relax via the 
emission of radiation (fluorescence) or via radiationless 
transitions (such a non-radiating process is the FRET). The 
energy that is dissipated by the excited donor molecule 
excites an acceptor molecule, which will eventually relax 
by the subsequent emission of a fluorescent photon at a 
red-shifted wavelength (Figure 2A). The efficiency of the 
transfer depends critically on the proximity of the donor 
and the acceptor groups, the Förster radius R0, which is 
defined as the intermolecular distance at which the FRET 
efficiency is 50% [5]. Values for R0 for donor-acceptor 
pairs range between 30 and 90 Å, which corresponds to 
the typical size of biologically relevant molecules. Hence, 
FRET is a sensitive approach for the study of intermolecular 
interactions between proteins, DNA or RNA and protein, 
or between DNA strands [6,7]. A variant of FRET is 
bioluminescence resonance energy transfer (BRET), where 
the acceptor molecule is excited by the bioluminescence 
generated by an enzymatic reaction [8,9].
Protein-protein interactions can also be analyzed using 
the two-hybrid system [10•]. In order to study the 
interaction of two proteins, X and Y, two fusion proteins are 
engineered. The first engineered protein consists of 
protein X fused via a peptide linker to the DNA-binding 
domain (DBD) of a transcription factor. Similarly, protein Y 
is linked to the activator domain (AD) of the transcription 
factor. Upon interaction of the proteins X and Y, the DBD 
and AD are brought into sufficient proximity to execute 
their function as a transcription factor, activating the 
expression of a reporter gene, which then can be detected 
by imaging (Figure 2B). However, in order to initiate gene 
transcription, the protein-protein interaction has to take 
place in the nucleus, hence non-nuclear proteins have to 
be targeted to the nucleus [11]. For the two-hybrid assay, 
any reporter gene can be used, for example, bioluminescent 
or fluorescent proteins in combination with optical 
imaging [12], enzyme systems that lead to the trapping 
of radiolabeled substrates detected by nuclear imaging 
techniques [13] or proteins that can be used in combination 
with magnetic resonance imaging (MRI) [14]. The use of 
enzymatic reporter systems is particularly attractive as 
high signal amplification can be achieved resulting in high 
sensitivity and high signal-to-background ratios.
Nuclear translocation of the interacting proteins is an 
inherent problem when using the two-hybrid assay. This 
problem can be overcome by the split ubiquitin assay, 
which even allows probing of membrane-bound protein-
protein interactions [15,16]. The system is based on the 
cleavage of conjugated ubiquitins by ubiquitin-specific 
proteases (UBPs). The interaction of the protein pair leads 
to the reconstitution of split ubiquitin, which is subsequently 
cleaved by the UBP. By engineering the cleaved fragment 
to comprise a nuclear transcription factor, translocation of 
this moiety to the nucleus is achieved where it will induce 
expression of the reporter gene (Figure 2C). The advantage 
of the split ubiquitin system is that protein interactions 
occurring in the cytosol or even at the membrane can be 
studied. An inherent problem with the two-hybrid assay (or 
the split ubiquitin variant thereof) is the fact that, because 
of the time lag of the reporter gene induction, protein 
interactions cannot be measured in real time. Similarly, the 
signal detected may not reflect the protein activity [3•].
The protein fragment complementation assay (PCA) is 
based on a split reporter protein that is reconstituted 
upon interaction of the target proteins X and Y to form a 
functioning reporter system (Figure 2D) [17]. PCA has been 
used by several research groups to demonstrate protein-
protein interactions. It is essential that small, monomeric 
proteins are used as split reporters in order to enhance the 
chances for proper reconstitution, including proper folding. 
Typical candidates are firefly luciferase [18] or Renilla 
luciferase [19], both of which have been used for in vivo 
applications of the assay. Luciferases are oxygenases 
that generate a bioluminescent signal upon processing 
their substrates: d-luciferin for firefly luciferase and 
coelenterazine for Renilla luciferase [2••]. An attractive 
feature of these systems is the efficient signal amplification 
due to the enzymatic substrate processing. This is 
an important prerequisite for the visualization and 
quantification of low-abundance events. A special variant 
of PCA is based on protein splicing, in which the complete 
reporter is reconstituted following the elimination of 
a polypeptide domain (intein) from within the primary 
translation product (Figure 2E).
Imaging signaling pathway activity in vivo: 
Selected examples 
Protein-protein interactions
Luker et al have applied the two-hybrid system to visualize 
the interaction of the tumor suppressor protein p53 and 
its protein counterpart, large T-antigen (TAg), in tumor-
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bearing mice using a double reporter system (Figure 3) 
[13,20•]. The p53 protein was fused to a DBD targeting 
the GAL-4 sequence on the DNA, while TAg was fused to 
the VP16 AD. The interaction of p53 with TAg led to the 
reconstitution of an active transcription factor consisting 
of the Gal4-DBD and the VP16-AD, which prompted the 
expression of the reporter construct composed of mutated 
herpes simplex virus-1 thymidine kinase (mHSV1-TK) fused 
to enhanced green fluorescent protein (EGFP). mHSV1-TK 
phosphorylates thymidine analogs, which are thereby 
trapped within the cell. This accumulation of these 
phosphorylated thymidine analogs, which is a measure for 
the activity of the reporter gene product, can be assessed 
by positron emission tomography (PET) in vivo following 
Figure 2. Assays for assessing the interaction of two proteins X and Y.
(A) Fluorescence energy resonance transfer (FRET) assessing the energy transfer from a donor molecule (D) to an acceptor molecule (A). Upon 
protein-protein interaction, fluorescence of the acceptor molecule will be detected when exciting the donor. (B) Two-hybrid assay: Protein-protein 
interaction leads to formation of a transcription factor consisting of a DNA-binding domain (DBD) and an activation domain (AD) driving the 
expression of a reporter gene via a promoter (Prom). (C) Split ubiquitin assay: Protein interaction leads to conjugation of ubiquitin (Ub) followed 
by proteolytic degradation by ubiquitin-binding proteases (UBPs). This releases a transcription factor (TF), which then translocates to the nucleus 
to induce the transcription of a reporter gene. (D) Protein fragment complementation assay (PCA) or split reporter assay: Two fragments of a split 
reporter (C- and N-termini: CRep and NRep) are fused to the interacting proteins. Dimerization leads to the reconstitution of a functional reporter. 
(E) PCA with intein excision: Similar to (D), but an intein sequence (Int) is excised from the primary transcription product in an intermediate step, 
which leads to the reconstitution of a functional reporter.
(Reproduced with permission from the University of Zürich.  2008 University of Zürich).
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the administration of [18F]-labeled fluorinated thymidine 
substrates. In this study, [18F]-penciclovir was used. 
The fluorescent reporter EGFP has been introduced for 
histological analysis. Mutation of HSV1-TK was required 
to enhance the sensitivity of the in vivo reporter assay: 
maximal enzymatic activity for the PET substrate used 
was considered a prerequisite for imaging protein–protein 
interactions in living mice. HeLa cancer cells stably 
transfected with the three constructs (the two constructs 
encoding the interacting fusion proteins and the reporter 
construct) were injected into the axilla of nude mice. The 
reporter construct was expressed under the control of a 
tetracycline-responsive trans-activator. The PET experiment 
was carried out 24 h after gene induction. The accumulation 
of the radiolabel in the tumor, indicative of p53-TAg 
interaction, could be monitored non-invasively with high 
sensitivity [13]. In control tumors with VP16-AD linked to 
a protein that did not interact with p53, no PET signal was 
observed. Only the p53-TAg interaction induced substantial 
expression of the reporter gene, underscoring the specificity 
of the approach.
The same transcriptional elements (GAL4-DBD and 
VP16-AD) have been used to induce the expression of 
firefly luciferase upon interaction of the nuclear proteins MyoD 
and ID. The myogenic regulatory protein MyoD is expressed 
in skeletal muscle, while ID is a negative regulator of 
myogenic differentiation. Interaction of the fusion proteins 
GAL4-ID and VP16-MyoD induced the transcription of 
the reporter gene firefly luciferase, which was under the 
control of the cytomegalovirus (CMV) promoter. Activity of 
the reporter enzyme reflecting MyoD-ID interaction could 
be monitored using bioluminescence imaging following 
administration of the substrate d-luciferin [12].
The PCA strategy using firefly luciferase as a split 
reporter has been applied for studying the same protein-
protein interaction, MyoD with ID, in mice [18]. Firefly 
luciferase consists of a large globular N-terminal domain 
and a smaller C-terminal separated by a wide cleft that 
constitutes the active site of the enzyme. Therefore, the 
split site was positioned in the peptide strand separating 
the two globular domains of the protein. Correspondingly, 
two fusion proteins were prepared: MyoD fused to the 
C-terminus (amino acids 438 to 554) and the ID protein 
fused to the N-terminal fragment of luciferase (amino acids 
1 to 437). Transfection of the cells with both fusion genes 
resulted in detectable bioluminescence signals in contrast 
to the transfection with only one of the two plasmids. 
Obviously, the MyoD-ID interaction led to complementation 
of the two luciferase fragments yielding a functional 
enzyme. Similar to split firefly luciferase, Renilla luciferase 
PCA has been developed as a reporter system to study 
protein-protein interactions [19].
In view of the important role of aberrant cell signaling in 
disease processes, it is not surprising that modulation 
of protein-protein interactions by low-molecular-weight 
drugs constitutes an attractive pharmacological strategy 
[21,22]. The feasibility of this concept has been studied 
in live animals using molecular imaging approaches. The 
interaction of FK506 binding protein 12 (FKBP12, also 
Figure 3. Two-hybrid assay for studying the interaction of the p53 tumor suppressor with large T antigen (TAg). 
Two gene constructs expressing the proteins p53 fused to the GAL4-DNA-binding domain (GAL4-DBD) and TAg fused to the activator domain 
(AD) VP16 were generated. Interaction of p53 with TAg constitutes a functional transcription factor driving the expression of a dual reporter system 
consisting of a mutated herpes simplex virus-1 thymidine kinase (mHSV1-TK) fused to enhanced green fluorescent protein (EGFP). HeLa cancer cells 
were transfected with the three constructs (two gene constructs encoding interacting fusion proteins plus the reporter gene construct comprising 
five GAL4 domains prior to a tetracycline-activatable promoter). Protein-protein-induced gene expression was monitored in vivo using positron 
emission tomography (PET) following the administration of [18F]-labeled thymidine substrates and ex vivo using fluorescence imaging [12].
(Reproduced with permission from the University of Zürich.  2008 University of Zürich).
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known as mammalian target of rapamycin, mTOR) and its 
partner FKBP12-rapamycin binding (FRB) domain is induced 
by rapamycin analogs and has been studied using the 
PCA with Renilla luciferase [23•] or firefly luciferase [24] 
as a split reporter system. For example, Renilla luciferase 
N- and C-terminal fragments were coupled to the two 
dimerization partners and transfected human 293T 
embryonic kidney cancer cells were injected into the 
mouse peritoneum. Prior to the infusion of rapamycin, 
no bioluminescent signal could be detected following 
intravenous administration of the substrate coelenterazine. 
Administration of rapamycin prompted a dose-dependent 
bioluminescent signal in the abdominal region of the 
mice 24 h and 48 h following dosing of the animals. This 
effect could be blocked by pretreatment with ascomycin, 
which inhibits FRB-FKBP12 dimerization, demonstrating the 
specificity of the assay [23•].
Targeting specific pathway molecules using 
genetic approaches
Cytosolic caspases, a family of cysteine proteases, play a 
role in propagating apoptotic signaling. Correspondingly, 
the assessment of the activity of the various caspases 
would constitute a measure of apoptotic pathway activity, 
which would be highly attractive for the evaluation of 
therapeutic interventions. Laxman et al have designed 
a genetically encoded caspase activity assay by fusing 
the reporter moiety (firefly luciferase) with an estrogen 
receptor regulatory (ER) domain [25]. The reporter is 
silenced in this ER-bound form. The linker between the 
luciferase and the ER domain contains the DEVD (aspartate-
glutamate-valine-aspartate) peptide motif that is cleaved 
by caspase-3, a protease expressed by most cells during 
apoptosis. Up-regulation of caspase-3 led to cleavage of 
the luciferase-DEVD-ER construct and the generation of a 
functional luciferase reporter, the activity of which could 
be probed by administration of d-luciferin (Figure 4). Proof-
of-principle of this approach has been demonstrated by 
stably transfecting human glioma cells, which were injected 
subcutaneously into nude mice. Induction of apoptosis 
by systemic administration of tumor necrosis factor-α 
(TNFα)-related apoptosis-inducing ligand (TRAIL) led to 
a significant bioluminescent signal within 1 h following 
the administration of the substrate d-luciferin. The ability 
to image caspase-3 activation non-invasively provides 
an attractive tool for studying the role of apoptosis in 
various diseases, as well as for the evaluation of potential 
therapeutic agents. 
Targeting specific pathway molecules using 
exogenous ligands
The strategy described above is based on genetic 
engineering and is thus confined to experimental studies in 
animals. In order to aid translation of a caspase imaging 
approach into the clinic, exogenous reporter probes 
would have to be used. In vitro and cellular studies have 
revealed that this is feasible in principle. Berger and 
co-workers have developed probes that are based on 
caspase selective inhibitors, as well as activatable probes 
that are based on enzymatic substrate turnover [26,27]. 
While this approach has provided valuable in vitro data, 
it remains to be demonstrated whether such or related 
probes targeting intracellular proteases can be used in living 
animals.
Metabolic/physiological response to receptor 
activation
While genetically encoded readouts for assessing signaling 
transduction pathways represent important tools for basic 
biomedical research as well as for the development of novel 
therapies, they are limited by the fact that they cannot be 
translated into the clinic. Clinical imaging strategies have to 
Figure 4. Monitoring caspase-3 activity in vivo using a luciferase reporter gene assay. 
The construct consists of firefly luciferase (F luciferase) flanked on both sides by mouse estrogen regulatory (ER) domains. The polypeptide linker 
chain comprises the caspase-3-specific peptide cleavage motif DEVD. Presence of the large ER moieties in the fusion protein inhibits luciferase 
activity. The expression of caspase-3 during apoptosis causes cleavage of the ER domains leading to activation of the reporter enzyme. Proof-of-
principle was demonstrated in murine tumor xenografts (D54 human glioma cells), which had been stably transfected with the reporter construct. 
Induction of apoptosis by administration of TNFα-related apoptosis inducing ligand (TRAIL) led to a bioluminescent signal that could be detected 
in vivo.
(Reproduced with permission from the University of Zürich.  2008 University of Zürich).
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be based on exogenous reporter ligands that target specific 
pathway molecules (see previous section). Currently, 
none of these ligands are available for widespread use in 
research or for clinical studies. Alternatively, physiological or 
metabolic readouts can be used as indicators of pathway 
activity.
Signaling activity ultimately translates into a morphological, 
physiological and/or metabolic phenotype that can be 
assessed using 'classical' imaging approaches. The 
assessment of such phenotypic readouts is associated with 
significant signal amplification and, therefore, provides 
an attractive window for visualizing ligand-receptor 
interactions. For example, the interaction of a neuro-
modulatory drug with its receptor will prompt an excitatory 
or inhibitory neural response associated with adaptations in 
energy demand, which can be probed by the measurement 
of local glucose and/or oxygen consumption using PET 
[28]. Alterations in metabolic activity on its own will 
induce changes in local brain perfusion to ensure the 
sufficient delivery of substrates and removal of metabolic 
products; altered neuronal activity will be reflected by 
adaptation of local hemodynamics via neuro-vascular 
coupling (Figure 5). Changes in brain perfusion can be 
monitored using PET, single photon emission computed 
tomography (SPECT) and MRI approaches [29]. 
These techniques, in particular functional MRI using 
pharmacological stimulation by neuroactive compounds 
(pharma fMRI), have become standard techniques for brain 
functional studies (for example, see [30-32]).
Figure 5.  System response to excitatory or inhibitory neuron-active drug. 
(A) Interaction of the neuro-modulatory ligand with its receptor, which can be monitored using positron emission tomography (PET) receptor 
occupancy studies, prompts a neuronal response. Local alterations in energy demand are matched by the adaptation of cerebral metabolism, 
which can be assessed by measuring the local cerebral glucose utilization (cerebral metabolic rate of glucose, CMRglu) or oxygen consumption 
(cerebral metabolic rate of oxygen, CMRO2) using PET or the turnover of high-energy phosphates, such as phosphocreatine (PCr) or 
adenosyltriphosphate (ATP), using [31P]-magnetic resonance spectroscopy (MRS). Vascular coupling leads to adaptations of regional cerebral 
blood flow (rCBF) and regional cerebral blood volume (rCBV), which can be assessed using functional magnetic resonance imaging (fMRI). 
(B) CNS activation in rat following administration of γ-amino butyric acid receptor A (GABAA-R) antagonist bicuculline showing the anatomical 
reference scan (left) and the drug-induced increases in CBV as a readout of receptor stimulation (right). Indicated regions of interest have been 
used for quantitative image analysis (adapted from Reese T, Bjelke B, Porszasz R, Baumann D, Bochelen D, Sauter A, Rudin M: Regional brain 
activation by bicuculline visualized by functional magnetic resonance imaging. Time resolved assessment of bicuculline-induced changes in 
local cerebral blood volume using an intravascular contrast agent. NMR Biomed (2000) 13(1):43-49.  2008 John Wiley & Sons Ltd). (C) Correlation 
of bicuculline-induced CBV response with receptor density in respective brain area. 
(Reproduced with permission from the University of Zürich.  2008 University of Zürich).
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A second example of a physiological response to receptor 
activation is hypoxic signaling. Tissue hypoxia is associated 
with a number of pathologies, including tumors, which 
in the initial phase exibit avascular growth unless they 
outgrow the nutrient and oxygen supply by molecular 
diffusion. In areas of low oxygen tension, the hypoxia 
inducible factor (HIF) signaling cascade is initiated 
by stabilizing HIF1α, which is degraded by oxygen-
dependent enzymes under normoxic conditions. Following 
dimerization with its counterpart HIF1β, an active 
transcription factor is formed, which induces a large 
number (more than 100) of downstream genes upon 
translocation to the cell nucleus [1]. One family of target 
genes is associated with angiogenesis, the formation of 
neo-vasculature, which is aimed at establishing blood 
supply to the hypoxic domains. The immature vessels are 
characterized by high vascular permeability, which can be 
assessed by measuring the leakage of a contrast agent or 
dye from the vascular bed into the interstitium. In fact, 
vascular permeability is commonly used as an indicator 
of the angiogenic potential in tumors, which is associated 
with malignancy. Vascular permeability assessment using 
dynamic contrast enhanced MRI (DCE-MRI) is a widely 
evaluated biomarker and has become a standard for 
assessing anti-angiogenic response [33•,34-36].
A third example of downstream readouts relates to 
apoptosis. In apoptotic cells, aminophospholipids 
(eg, phosphatidylserine, PtdSer) are redistributed to the 
outer leaflet of the cell membrane [37•]. PtdSer therefore 
constitutes an attractive target for selectively labeling 
apoptotic cells. This is achieved by the administration of 
annexin-5A (or related compounds) labeled with either 
a radio-ligand [38], a fluorescent dye [39] or an MRI 
contrast agent [40]. Radio-labeled annexin-5A is currently in 
clinical development as a potential radio-diagnostic.
Cell signaling via second messengers
A fundamental signal transduction mechanism is based on 
second messengers: the ligand-receptor interaction leads 
to the activation of membrane-bound phospholipase-2 
(PL2), which cleaves phospholipids of the cell membrane, 
such as phosphatidylinositol-bisphosphate (PtdIP2) to 
inositol-triphosphate (IP3) and diacylglycerol (DG), which 
play the role of 'second messengers' in the cytosolic 
signaling cascades. IP3 induces the release of calcium from 
intracellular stores, prompting a number of downstream 
events. Efficient pathways for the removal of second 
messengers are required in order to control signaling: IP3 
is inactivated by stepwise dephosphorylation to inositol, 
while DG is phosphorylated to form phosphatidic acid. 
Both inactivated second messengers are then recycled to 
replenish the membrane-bound PtdIP2 pool [41]. Intracellular 
levels of IP3 and DG are low because of rapid elimination 
and are not amenable to direct visualization using non-
invasive imaging.
IP3 turnover can be probed by inhibiting inositol-1-
phosphatase following lithium administration. This leads 
to an accumulation of inositol-1-phosphate (IP), which can 
be measured using [31P] magnetic resonance spectroscopy 
(MRS). This method has been used in vivo to study the 
acute effects of CNS drugs in rats. Pretreatment of the 
animals with a low dose of lithium chloride led to a modest 
two- to three-fold increase in cortical IP levels 24 h later 
due to basal signaling activity. Subsequent administration 
of the cholinergic agonist pilocarpine prompted cortical IP 
levels to increase 40-fold within 60 min, which could be 
detected in a straightforward manner in vivo as an increase 
in the phosphomonoester signal intensity using [31P] MRS 
[42].
Conclusion
Imaging, including molecular imaging, plays an important 
role in the evaluation of therapeutic interventions. Tasks 
involve the characterization of the receptor status in the 
healthy and diseased tissue as part of target validation 
or for stratification of patient populations. For example, 
in order to use the monoclonal antibody trastumazab 
for treating breast cancer, up-regulation of its molecular 
target, the Her2/neu receptor, has to be demonstrated 
for the patient to be treated [43]. Secondly, it has to be 
demonstrated that a drug or drug candidate is reaching 
its target at sufficient concentration to prompt a 
pharmacological effect. Finally, imaging methods are used 
to document drug efficacy on the basis of morphological, 
physiological or metabolic readouts. Today, such imaging 
readouts serve primarily as biomarkers rather than clinical 
endpoints, providing an objective quantitative measure of 
treatment efficacy. The US Food & Drug Administration 
(FDA) in its Critical Path Initiative sees a critical role for 
biomarkers, including imaging biomarkers, for speeding up 
the drug discovery and development process in providing 
evidence for target validation, elucidating the mechanism 
of action of drug candidates, demonstrating proof-of-
principle of a therapeutic intervention, stratifying patient 
populations and evaluating therapy response or eventual 
side effects in early clinical trials [44••,45••]. Yet, it should 
be kept in mind that biomarkers do not substitute for the 
clinical endpoints that are required for regulatory approval 
of a new therapy.
The measurement of pathway activity constitutes an 
important bridge between the receptor and drug imaging 
and the visualization of therapy efficacy based on a 
system response. It provides essential information on 
the mechanism of action of an intervention; however, the 
imaging of signal transduction faces two principal obstacles: 
(i) signaling pathways are inherently intracellular, hence 
potential exogenous reporter probes have to reach the 
cytosolic compartment. Not surprisingly, most of the assays 
used for pathway imaging are based on genetically encoded 
reporters, the expression (eg, using the two-hybrid system) 
or function of which (eg, using PCA) is initiated by the 
intracellular molecular event to be studied; and (ii) many 
species in signaling cascades occur at low concentrations 
and hence visualization of these processes constitutes a 
major sensitivity issue. In this regard, the targeting of 
enzymes, which activate a significant number of substrates 
and thereby achieve massive signal amplifications, 
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is attractive. A general issue with molecular imaging 
approaches is that the use of reporters, both genetically 
encoded and exogenous, may alter the system under 
investigation. 
In the post-genomic era, it is assumed that there are 
in the order of 10,000 druggable targets (receptors, 
enzymes, etc) [46]. The information about ligand-target 
interaction is then propagated within the cell through the 
interplay of only a few hundred signaling pathways that 
are interconnected in a complex manner. Systems biology 
addresses such intra- and intercellular networks. The 
availability of noninvasive imaging assays for studying 
various signaling pathways would constitute a 'generic' 
toolset that could be used for a multitude of potential drug 
targets. Such readouts would provide unique mechanistic 
information in a temporo-spatially resolved manner in 
the intact organism, with all regulatory processes in 
place. Currently, molecular imaging of signal transduction 
processes is in its infancy and only a few of these assays 
are available. It is expected that the field will rapidly evolve 
to become an important technology for the drug developer. 
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